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Abstract
Purpose—Racial minority cancer patients may experience underuse of antiemetic medications to 
prevent chemotherapy-induced nausea and vomiting (CINV). In addition to its adverse 
implications for quality of life, antiemetic underuse may contribute to observed disparities in acute 
illness during chemotherapy. To understand the potential contribution of CINV prophylaxis to 
breast cancer disparities, we assessed racial variation in potent antiemetic use and post-
chemotherapy utilization related to CINV, and the relationship between the two.
Methods—We used SEER-Medicare data to evaluate health care utilization in the 14 days 
following chemotherapy initiation among black and white women receiving highly emetogenic 
chemotherapy for breast cancer. We used modified Poisson regression to assess the relationship 
between: 1) race and CINV-related utilization; and 2) NK1 use and CINV-related utilization, 
overall and stratified by race. We report adjusted risk ratios (aRR) and 95% confidence intervals 
(CI).
Results—The study included 1,130 women. Black women were 11% less likely than white 
women to use neurokinin-1 receptor antagonists (NK1s) for CINV prophylaxis (p=0.02); however, 
Corresponding Author and Reprint Requests: Devon K. Check, University of North Carolina at Chapel Hill, Gillings School of Global 
Public Health, Department of Health Policy and Management, CB#7411, Chapel Hill, NC 27599, dkcheck@unc.edu, Phone: 
610-613-7784. 
Disclosures
None.
HHS Public Access
Author manuscript
Support Care Cancer. Author manuscript; available in PMC 2017 December 01.
Published in final edited form as:
Support Care Cancer. 2016 December ; 24(12): 4839–4847. doi:10.1007/s00520-016-3338-4.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
they experienced fewer CINV-related encounters following chemotherapy (unadjusted RR:0.63, 
95%CI:0.40–0.99; p=0.05). After adjustment for clinical covariates, estimates were similar but no 
longer statistically significant (p=0.07). Among white women NK1 use was associated with 
increased CINV-related utilization (aRR NK1 users vs. non-users: 1.35, 95%CI: 1.07–1.69, 
p=0.01), likely resulting from unmeasured confounders.
Conclusion—Black women were less likely to use NK1s and CINV-related services. Racial 
variation in CINV-related services use may be partly explained by differential symptom reporting 
or access to care.
Introduction
In the United States, breast cancer is the most common malignancy among women.[1] 
Advancements in early detection and treatment have improved breast cancer outcomes, 
leading to five-year survival rates of 99% for local-stage disease and 85% for regional-stage 
disease.[2] Thus the goals of breast cancer care have expanded from treating the disease to 
preserving women’s quality of life (QOL) during treatment. This includes managing 
symptoms related to breast cancer and its treatment, an area increasingly recognized as 
critical to high-quality breast cancer care.[3–5]
Research suggests that cancer patients of minority race may receive inadequate symptom 
management. Studies have documented racial/ethnic disparities in outcomes related to 
symptom burden and severity, [6,7] adequacy of pain treatment, [8–10] and patients’ 
perceived unmet need for supportive care.[11] Other studies have demonstrated that minority 
patients may underuse medications to control treatment-related symptoms. In particular, 
evidence suggests that black patients may be more likely than white patients to experience 
underuse of guideline-recommended antiemetic medications to prevent chemotherapy-
induced nausea and vomiting (CINV), which cancer patients have consistently cited as a 
major and fearful concern.[12] Specifically, Samuel and colleagues found that among 
colorectal, lung, and prostate cancer patients being treated with chemotherapy in the 
Veterans Affairs system, black patients were less likely than white patients to use 5HT3 
receptor antagonists.[13] Gomez and colleagues also found racial and income disparities in 
use of both 5HT3 antagonists and dexamethasone among lung cancer patients in Texas.[14] 
More recently, we documented disparities in use of neurokinin-1 receptor antagonists 
(NK1s), a newer and more potent class of antiemetics recommended for use with highly 
emetogenic chemotherapy regimens, among women with early-stage breast cancer, a 
population that frequently receives highly emetogenic chemotherapy.[15]
In addition to the known implications for patients’ QOL, racial disparities in CINV 
prophylaxis may perpetuate well-documented disparities in other dimensions of breast 
cancer care. Namely, research has demonstrated that black women may be less likely to 
adhere to recommended chemotherapy regimens and schedules[16–19] and more likely to 
experience hospitalizations and acute illness during treatment with chemotherapy.[19] 
Others have suggested that minority women’s difficulty accessing medications to control 
treatment-related side effects may help to explain differential treatment experiences.[20] 
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However, the link between disparities in side effect control and treatment experiences of 
breast cancer patients has not been empirically studied.
With the objective of furthering understanding of how racial disparities in CINV 
management may contribute to racial disparities in breast cancer treatment experiences, we 
assessed racial differences in post-chemotherapy health care utilization related to CINV, 
including use of inpatient, emergency department or outpatient services. We also assessed 
the role of prophylactic NK1 use in potentially attenuating these differences. Finally, we 
assessed racial differences in any post-chemotherapy health care utilization overall, and for 
other common breast cancer treatment-induced side effects to determine whether any 
potential differences in utilization for CINV could be explained by differential use of 
services more broadly.
Methods
Data
We used the National Cancer Institute’s Surveillance Epidemiology and End Result (SEER) 
database linked with Medicare fee-for-service claims from 2006–2012. The SEER program 
consists of population-based cancer registries and represents 28% of the population with 
cancer. SEER data are merged with fee-for-service Medicare claims.[21] Data for our 
analysis came from the Prescription Drug Event records, Medicare Provider Analysis and 
Review (MEDPAR) file for inpatient services, the Hospital Outpatient Standard Analytic file 
for outpatient facility services, the 100% Physician/Supplier file for physicians’ services, 
and the Durable Medical Equipment (DME) File.
Our study was conducted in accordance with a SEER-Medicare data use agreement and was 
approved by the Institutional Review Board at the University of North Carolina at Chapel 
Hill.
Sample
We included women aged 65 years and older who were diagnosed with stage I, II, or III 
breast cancer between January 1, 2007 and December 31, 2011. Eligible women were: (1) 
not diagnosed at autopsy or death; (2) continuously enrolled in Medicare Parts A and B for 6 
months before and 12 months after diagnosis; (3) continuously enrolled in Medicare Part D 
for 12 months after diagnosis; and (4) not enrolled in an HMO for 6 months before and 12 
months after diagnosis. There were 27,160 women meeting these criteria. From this sample, 
we restricted our analysis to women who received surgery (mastectomy or breast conserving 
surgery) and initiated chemotherapy within 6 months of diagnosis (n=4,651). The analysis 
was further restricted to women whose first cycle of adjuvant chemotherapy included an 
anthracycline and cyclophosphamide (n=1,569), as guidelines have consistently 
recommended use of an NK1 for these regimens throughout the study period.[22–26] 
Because of the small proportion of non-black minorities (n=118), the study was restricted to 
black and white women (n=1,451). Finally, because Part D claims are available starting on 
01/01/2007, women in our sample initiated chemotherapy on or after February 1, 2007 
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(n=1,130). This enabled us to observe Part D claims for antiemetics in the 30 days before 
chemotherapy initiation. A CONSORT diagram is displayed in Figure 1.
Measures
The primary outcome was post-chemotherapy health care utilization, measured as any 
inpatient or outpatient claims (including emergency department claims) in the 14 days after 
the first chemotherapy infusion. We were specifically interested in CINV-related utilization, 
identified by claims with an associated diagnosis of nausea and vomiting (ICD-9 codes 
787.0–787.02), volume depletion (ICD-9 code 276.5), dehydration (ICD-9 code 276.51), or 
hypovolemia (ICD-9 code 276.52) in the 14 days after the first chemotherapy infusion. We 
chose 14 days as the window of observation because adjuvant chemotherapy regimens for 
breast cancer should be given no more frequently than every 14 days.[27]
The main independent variables in our analysis were race (black or white), as reported by 
patients at the time of diagnosis and included in the SEER data, and prophylactic NK1 use. 
NK1 users were defined as having a Medicare Part D claim for aprepitant (oral formulation), 
as identified by the drug name, in the 30 days before or on the day of chemotherapy 
initiation. Alternatively, they had a Part B claim for aprepitant in the 30 days before or on 
the day of chemotherapy initiation, as identified using Health Care Common Procedure 
Coding System codes (J8501) and as recorded in the outpatient, physician services or 
durable medical equipment claims files. Finally, NK1 users could have a claim for 
fosaprepitant (IV formulation) (C9242, J1453) on the day of chemotherapy initiation, as 
recorded in the outpatient or physician services files. We focused on the first cycle of 
chemotherapy because we were interested in measuring use of NK1s for CINV prophylaxis 
rather than use that may be in response to symptoms experienced during a previous cycle.
Covariates included patients’ demographic and clinical characteristics: age at diagnosis, 
American Joint Committee on Cancer stage, tumor grade, hormone receptor status, lymph 
node involvement, comorbid illness (calculated using the Klabunde modification of the 
Charlson score based on patients’ Medicare Part A and B claims pre-diagnosis)[28], and 
year of chemotherapy initiation. We also included information on patients’ marital status. 
Area-level measures of socioeconomic status (SES) included census tract-level high school 
completion rate, and median income, obtained from the 2000 census. Geographic variables 
were U.S. region of residence, and extent of urbanization in patients’ neighborhoods.
Statistical Analysis
We examined the distribution of patient characteristics between racial groups using chi-
squared tests. To directly estimate risk ratios with robust error variance, we used modified 
Poisson regression[29] to assess the relationships between race, NK1 use, and post-
chemotherapy health care utilization, controlling for relevant patient characteristics. We 
present unadjusted risk ratios (RR) and adjusted risk ratios (aRR) with 95% confidence 
intervals (CI) for post-chemotherapy health care utilization, comparing black and white 
women and NK1 users versus non-users.
Check et al. Page 4
Support Care Cancer. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Accounting for SES—The Institute of Medicine (IOM) defines racial healthcare 
disparities as differences in quality of care provided to patients of different racial groups that 
are not justified by clinical need or preferences of patients. [30] Analytic approaches to 
implement this definition use statistical models that control for differences in health status 
(e.g. comorbidity, age) and clinical need (e.g., tumor characteristics) and, if available, 
preferences for care, between racial groups.[31,32,13] This approach recognizes the 
mediating role of an individual’s SES and SES-related factors, that is, minorities tend to 
have lower SES profiles than whites, and such differences can impact care received. 
Excluding SES-related factors from estimates of the effect of race on care may more 
accurately reflect minority patients’ experiences of receiving care.
Consistent with the IOM definition of health care disparities, our primary models adjusted 
for clinical characteristics (age at diagnosis, year of chemotherapy initiation, tumor 
characteristics, and medical comorbidity).[32] We did not adjust for census tract-level 
measures of SES or in our primary models; neither did we adjust for other potential 
mediators of disparities, namely geographic factors (U.S. region of residence and 
metropolitan versus non-metropolitan residence) and marital status. However, because it is 
important to understand where disparities in care might arise, we conducted secondary 
analyses to assess whether differences in census tract-level SES, marital status, or geography 
attenuated potential racial differences in utilization.
Sensitivity Analyses
To ensure we were not incorrectly classifying claims associated with CINV prophylaxis (i.e., 
NK1 administration) for a women’s second chemotherapy cycle as outpatient utilization for 
the treatment of CINV, in sensitivity analyses, we restricted the outcome measurement 
window to 7 days post-chemotherapy administration. In addition, we restricted CINV-related 
utilization to claims with a primary or secondary diagnosis related to CINV.
Results
Among the 1,130 women who met our eligibility criteria, 1,015 (90%) were white and 115 
(10%) were black. Compared to white women, black women were less likely to be married 
(25% versus 53%, p<0.0001). There were also racial differences in census tract-level income 
and education and U.S. region of residence (p<0.0001). Regarding CINV prophylaxis, black 
women were 13% less likely to use an NK1 (p<0.05) (Table 1). Overall, 91% of women had 
outpatient visits in the 14 days following their first chemotherapy infusion and 23% of 
women were treated for CINV. CINV-related utilization consisted largely of claims for 
outpatient visits (22%); only 2% of women had ED or inpatient claims related to CINV.
CINV-Related Utilization
In unadjusted analysis, compared to white women, black women had a 37% decreased risk 
of experiencing any CINV-related utilization (RR: 0.63, 95% CI: 0.40–0.99) (Table 2). 
Racial differences in CINV-related utilization did not persist in our primary model adjusting 
for clinical characteristics (aRR: 0.66, 95% CI: 0.42–1.04, p=0.07) or in the secondary 
model adjusting for clinical characteristics along with SES, marital status, and geographic 
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variables (aRR: 0.69, 0.42–1.14, p=0.12; data not shown). In both adjusted models, 
estimates were similar to the unadjusted results, but they were no longer statistically 
significant due to widening confidence intervals.
Unexpectedly, compared to women who did not receive an NK1 for the prevention of CINV, 
women who did experienced higher CINV-related utilization as measured through post-
chemotherapy inpatient or outpatient visits for nausea and vomiting, volume depletion, 
dehydration or hypovolemia (aRR: 1.34, 95%CI: 1.07–1.68, p=0.01). This positive 
relationship persisted among white women (aRR: 1.33, 95%CI: 1.06–1.69, p=0.01), but it 
was not statistically significant among black women (aRR: 1.08, 95% CI: 0.34–3.41, 
p=0.90) (data not shown).
In the sensitivity analysis restricting CINV-related utilization to claims with a primary or 
secondary (versus any) diagnosis code related to CINV, the racial difference in utilization 
was larger than in the primary model, but still statistically non-significant (aRR: 0.52, 95% 
CI: 0.26–1.05; p=0.07). In an additional sensitivity analysis restricting the window of 
observation for CINV-related claims to 7 days post-chemotherapy initiation, estimates were 
similar to those of the main model (aRR: 0.61, 95% CI: 0.25–1.47, p=0.30).
Other Post-Chemotherapy Utilization
In analyses examining racial differences in any post-chemotherapy health care utilization, 
we found no differences in either unadjusted or adjusted models (aRR: 0.95, 95%CI: 0.89–
1.03, p=0.21) (Table 2). There were also no statistically significant racial differences in 
women’s outpatient utilization for other common chemotherapy-induced side effects. 
Specifically, black women were no less likely than white women to receive treatment for 
neutropenia (aRR: 0.90, 95% CI: 0.71–1.16, p=0.42) or fatigue (aRR: 0.45, 95% CI: 0.14–
1.44, p=0.18).
Discussion
We observed possible racial variation in use of outpatient services for CINV during the first 
cycle of highly emetogenic chemotherapy, with black women being less likely to receive 
CINV-related care in the post-chemotherapy period. This finding was counter to our 
hypothesis that black women would be more likely to experience CINV-related utilization 
because of evidence of potential underuse of NK1s for CINV prophylaxis among black 
patients. Instead, in this SEER-Medicare sample, black women were at lower risk for both 
using an NK1 and for receiving treatment for CINV. Although the racial difference in CINV-
related utilization was not statistically significant after adjustment for covariates, estimates 
were still consistent with lower utilization among black patients. There are several potential 
explanations for our findings.
One explanation for racial variation in cancer-related health services use is that black cancer 
patients are less likely to access care in general, [30] for example, adjuvant treatment for 
breast cancer.[33] Similar patterns have been observed in other cancers, with black patients 
more likely to refuse lung cancer treatment.[34] However, it seems unlikely that racial 
differences in care-seeking behavior fully explain the variation we observed, because our 
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sample is limited to women who underwent surgery and initiated adjuvant chemotherapy. 
Moreover, we observed no racial variation in the use of any outpatient services during the 14 
days following chemotherapy initiation. This suggests that even among women who chose to 
undergo multi-model therapy, differences in CINV-related health care utilization exist.
Because racial differences in general or cancer care-seeking behavior do not appear to 
explain racial variation in CINV-related services use, it may be that the variation we 
observed is specific to CINV or symptom management. There are two reasons black women 
may be less likely to have claims with diagnosis codes related to CINV. First, black and 
white women may be at equal risk of experiencing CINV, but black women may be less 
likely to report this experience to their providers.[35] Differential reporting could result from 
differential thresholds for reporting symptoms across demographic or cultural 
characteristics.[36] Alternatively, minority and low-income women may have competing 
health or social concerns that affect their likelihood of reporting symptoms and/or 
prioritizing their management.[36] Others have suggested that vulnerable populations, 
including minorities, may receive suboptimal care due to decreased self-efficacy, defined as 
patients’ perceived ability in obtaining needed information and attention regarding their 
medical concerns.[37] In a study by Maly and colleagues, perceived self-efficacy was 
positively associated with nausea resolution in a cohort of low-income women with breast 
cancer.[38] In any case, it is ultimately physician’s awareness of symptoms that leads to 
discussion of treatment options with the patient, thereby facilitating symptom resolution. 
Thus, if minority patients are less likely to mention symptoms for any reason, they may be 
less likely to receive treatment for their symptoms, which could explain the lower incidence 
of CINV-related claims for black women in our data. A second potential explanation is that 
the black women in our sample may differ from white women with respect to unmeasured 
factors (e.g., body mass index), which could affect the incidence of treatment-induced side 
effects like CINV.[36,39,40] Higher rates of obesity could also lead to chemotherapy under-
dosing among black women, [41] which could decrease the incidence of side effects like 
CINV.
Reporting bias could also occur at the provider level. Our measures of health care utilization 
rely on providers’ coding of diagnoses. If providers are less likely to code nausea and related 
conditions among black patients, for example, due to competing or more pressing health 
concerns, rates of CINV could appear artificially low in black patients.
We did not observe statistically significant racial differences in patients’ receipt of treatment 
for fatigue or neutropenia, side effects commonly experienced among breast cancer patients 
including those in our sample. Our lack of observation of a statistically significant 
relationship between race and fatigue-related services use may be due to our small sample 
size, as estimated risk ratios were consistent with substantial racial variation. Specifically, 
black patients were 55% less likely than white patients to have claims related to fatigue. 
Racial differences in use of services related to neutropenia were smaller (10%), however, 
neutropenia is often not symptomatic and thus more commonly diagnosed through routine 
post-chemotherapy blood testing. Therefore, it is not clear whether neutropenia-related 
claims capture testing for the condition or patients’ experience of neutropenia-related 
infection.
Check et al. Page 7
Support Care Cancer. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The positive association between prophylactic NK1 use and CINV-related utilization was 
also surprising. A possible explanation is that we inadvertently captured claims with 
associated CINV diagnosis codes used to justify the prophylactic administration of 
antiemetics. This seems unlikely, however, as our observation window begins the day after 
chemotherapy initiation, and extends for 14 days. Adjuvant chemotherapy regimens for 
breast cancer should be given no more frequently than every 14 days; thus, we should not 
have captured claims for antiemetic administration during a women’s second cycle of 
chemotherapy. Therefore, we suspect confounding – specifically confounding by indication - 
may account for this relationship. For example, patients’ (or their providers’) level of 
concern about CINV might help to explain why patients who receive NK1s are also more 
likely to subsequently receive care related to the side effect. Our data suggest that white 
patients may be more likely to both use NK1s to prevent CINV and be treated for CINV, 
raising the question of whether black women are not being identified as being in need of 
CINV prevention and treatment. It is also possible that black women are concentrated within 
providers or systems where it may be more difficult to access high quality cancer care, [42] 
including medications to prevent side effects and services to address them. Black women 
may also experience access barriers that make both obtaining NK1s and side effect-related 
care more difficult.
Our study has several limitations. First, we restricted our cohort to fee-for-service Medicare 
beneficiaries with Part D coverage. It is unknown whether our findings generalize to 
younger women, Medicare beneficiaries enrolled in an HMO or women without prescription 
drug coverage through Part D. In particular, disparities may be even larger in samples that 
are more diverse with respect to insurance coverage. [43] Second, we focused on NK1 
receptor antagonist use as an indicator of CINV prophylaxis. We did so because NK1s are, 
according to guidelines, effective only in combination with two other less potent antiemetics 
(5HT3 antagonists and dexamethasone). However, our measure did include less potent 
antiemetics without an NK1. It is possible that patients who used an NK1 did not use it 
combination with less potent antiemetics. Third, we were unable to account for patients’ 
need for CINV related-care (i.e., their clinical experience with CINV). Fourth, our use of 
claims data prevented our ability to measure other clinically meaningful outcomes, for 
example, early termination of or withdrawal from chemotherapy, as it is not possible to 
determine a woman’s intended chemotherapy regimen or duration. Finally, only 115 black 
women met our study inclusion criteria, which might have resulted in our lacking statistical 
power for some comparisons.
These limitations not withstanding, we present novel data about possible racial variation in 
receipt of CINV-related care following the first cycle of highly emetogenic adjuvant 
chemotherapy for early-stage breast cancer. This variation may point to racial differences in 
women’s experience with CINV and their need for its treatment, their preferences for 
seeking care related to CINV, or their ability to obtain needed care for CINV and, potentially 
other symptoms. Thus, our data suggest that there may be a need for increased awareness 
and assessment of common side effects during post-treatment visits to ensure patients’ 
supportive care needs are met. Future research should assess whether black women’s 
relatively lower use of CINV-related medications and services is consistent with their 
informed preferences, or whether they may be experiencing barriers to access of needed 
Check et al. Page 8
Support Care Cancer. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
services. In addition, determining the role of women’s side effect experiences in contributing 
to disparities in important breast outcomes, for example patient-reported QOL and treatment 
adherence represents a novel area for future research.
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Figure 1. 
CONSORT Diagram
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Table 1
Sample Characteristics and NK1 Use, by Race
White Black
Number of Patients 1,015 115
Demographic Characteristics (%)
Age at Cancer Diagnosis
 65–66 20.7 25.2
 67–68 24.7 24.4
 69–71 25.1 22.6
 72–91 29.4 27.8
Marital Status at Diagnosisa
 Married/Partnered 52.9 25.2
 Non Married/Partnered 42.5 --
 Unknown 4.6 --
Median Household Income in Census Tract of Residencea
 $0–32,791 21.6 53.0
 $32,972–44,039 25.5 --
 $44,040–58,436 -- 13.0
 $58,437–188,340 27.1 --
 Unknown -- 0
Proportion of Adult Residents with No High School Degree in Census Tract of Residencea
 1.22–9.69% 27.4 --
 9.70–16.57% 26.7 --
 16.58–27.88% -- 30.4
 27.89–75.17% 20.3 57.4
 Unknown -- 0
Residence
 Metropolitan County 74.8 82.6
 Non-Metropolitan County 25.1 16.4
U.S. Region
 Northeast 19.4 20.0
 Midwest 18.0 14.8
 West 37.4 14.8
 South 25.1 50.4
Clinical Characteristics
Year of Chemotherapy Initiationa,b
 2007 28.9 31.3
 2008 20.1 20.9
 2009 17.0 18.3
 2010 14.8 11.3
 2011 15.4 --
 2012 3.8 --
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White Black
Charlson Comorbidity Scorea
 0 78.4 75.7
 1 17.2 --
 >1 4.3 --
Cancer Stage
 Stage I 12.8 10.4
 Stage II 53.6 56.5
 Stage III 33.6 33.0
Hormone Receptor Statusa
 HR positive 67.0 62.6
 HR negative 28.7 --
 Unknown 3.7 --
Tumor Gradea
 Low 10.3 --
 Intermediate 40.1 33.9
 High 45.9 56.5
 Unknown 4.3 --
Lymph Node Involvementa
 Yes 70.9 67.0
 No 27.7 --
 Unknown 1.4 --
CINV Prophylaxis
NK1 Receptor Antagonist Use
 Yes 41.0 27.8
 No 59.0 72.2
aCells containing proportions that reflect Ns<11 or information that would allow Ns<11 to be derived have been suppressed (--) to protect patients’ 
identities
bA small proportion of patients initiated chemotherapy in 2012 because we only have SEER data on patients diagnosed through December 2011. 
Thus, only patients who received chemotherapy within the first 6 months of 2012 are included in our sample.
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